NASDAQ:TARS

Tarsus Pharmaceuticals News Headlines

$28.56
+0.33 (+1.17 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$28.29
Now: $28.56
$28.87
50-Day Range
$27.37
MA: $32.97
$40.15
52-Week Range
$15.32
Now: $28.56
$63.69
Volume8,552 shs
Average Volume39,244 shs
Market Capitalization$585.57 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Tarsus Pharmaceuticals (NASDAQ TARS) News Headlines Today

SourceHeadline
 Analysts Anticipate Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) to Announce -$0.64 Earnings Per Share Analysts Anticipate Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) to Announce -$0.64 Earnings Per Share
americanbankingnews.com - April 8 at 4:25 AM
Tarsus Pharmaceuticals (NASDAQ:TARS)  Shares Down 7.3% Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Down 7.3%
americanbankingnews.com - April 7 at 3:10 PM
Tarsus Pharmaceuticals, Inc.s (NASDAQ:TARS) Lock-Up Period Set To Expire  on April 14thTarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Lock-Up Period Set To Expire on April 14th
americanbankingnews.com - April 7 at 1:18 AM
Tarsus Pharmaceuticals (NASDAQ:TARS) Sees Large Volume IncreaseTarsus Pharmaceuticals (NASDAQ:TARS) Sees Large Volume Increase
americanbankingnews.com - April 5 at 12:06 PM
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Recommendation of "Buy" from AnalystsTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Recommendation of "Buy" from Analysts
americanbankingnews.com - April 1 at 6:40 AM
Tarsus Pharmaceuticals, Inc. Reports Full-Year 2020 Financial Results and Business and Clinical UpdatesTarsus Pharmaceuticals, Inc. Reports Full-Year 2020 Financial Results and Business and Clinical Updates
finance.yahoo.com - March 31 at 4:56 PM
Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap Up to $27.37Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap Up to $27.37
americanbankingnews.com - March 31 at 11:00 AM
Tarsus Pharmaceuticals (NASDAQ:TARS) Trading Down 6.6%Tarsus Pharmaceuticals (NASDAQ:TARS) Trading Down 6.6%
americanbankingnews.com - March 30 at 12:42 PM
Tarsus Pharma Partners With LianBio For TP-03 In Greater China For Eye DiseasesTarsus Pharma Partners With LianBio For TP-03 In Greater China For Eye Diseases
markets.businessinsider.com - March 30 at 9:21 AM
Tarsus Pharmaceuticals and LianBio Announce Strategic Partnership to Develop and Commercialize TP-03 in Greater China for the Treatment of Demodex Blepharitis and Meibomian Gland DiseaseTarsus Pharmaceuticals and LianBio Announce Strategic Partnership to Develop and Commercialize TP-03 in Greater China for the Treatment of Demodex Blepharitis and Meibomian Gland Disease
finance.yahoo.com - March 29 at 6:20 PM
Sorrento Therapeutics (NASDAQ:SRNE) vs. Tarsus Pharmaceuticals (NASDAQ:TARS) Critical ContrastSorrento Therapeutics (NASDAQ:SRNE) vs. Tarsus Pharmaceuticals (NASDAQ:TARS) Critical Contrast
americanbankingnews.com - March 27 at 4:40 AM
Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap Down to $30.50Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap Down to $30.50
americanbankingnews.com - March 26 at 12:02 PM
Tarsus Pharmaceuticals (NASDAQ:TARS) Sees Strong Trading VolumeTarsus Pharmaceuticals (NASDAQ:TARS) Sees Strong Trading Volume
americanbankingnews.com - March 25 at 11:19 AM
Visionary Ventures Closes Fund II with $114MM in Committed CapitalVisionary Ventures Closes Fund II with $114MM in Committed Capital
finance.yahoo.com - March 23 at 1:41 PM
 Analysts Expect Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Will Announce Earnings of -$0.60 Per Share Analysts Expect Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Will Announce Earnings of -$0.60 Per Share
americanbankingnews.com - March 21 at 10:12 PM
Financial Comparison: Tarsus Pharmaceuticals (NASDAQ:TARS) and BioNTech (NASDAQ:BNTX)Financial Comparison: Tarsus Pharmaceuticals (NASDAQ:TARS) and BioNTech (NASDAQ:BNTX)
americanbankingnews.com - March 17 at 10:18 PM
Tarsus Pharmaceuticals, Inc. (TARS)Tarsus Pharmaceuticals, Inc. (TARS)
realmoney.thestreet.com - January 28 at 6:19 PM
Tarsus Pharmaceuticals, Inc.Tarsus Pharmaceuticals, Inc.
cnbc.com - January 16 at 8:20 PM
Tarsus Pharmaceuticals, Inc. Appoints Dianne Whitfield as Chief Human Resources OfficerTarsus Pharmaceuticals, Inc. Appoints Dianne Whitfield as Chief Human Resources Officer
finance.yahoo.com - January 7 at 1:36 PM
Tarsus Pharmaceuticals, Inc. to Present at the 2021 ICR Virtual ConferenceTarsus Pharmaceuticals, Inc. to Present at the 2021 ICR Virtual Conference
feeds.benzinga.com - January 5 at 5:41 PM
Tarsus Pharmaceuticals, Inc. Announces Type C Meeting with FDA Regarding NDA Submission Requirements for Lead Candidate TP-03Tarsus Pharmaceuticals, Inc. Announces Type C Meeting with FDA Regarding NDA Submission Requirements for Lead Candidate TP-03
finance.yahoo.com - December 23 at 8:55 AM
Tarsus Pharmaceuticals, Inc. Announces Inclusion in the Russell 3000® Index and Russell 2000® IndexTarsus Pharmaceuticals, Inc. Announces Inclusion in the Russell 3000® Index and Russell 2000® Index
finance.yahoo.com - December 21 at 12:01 PM
Tarsus Pharmaceuticals Inc.Tarsus Pharmaceuticals Inc.
barrons.com - December 9 at 9:28 PM
Tarsus Pharmaceuticals, Inc. Appoints Wendy Yarno to Board of DirectorsTarsus Pharmaceuticals, Inc. Appoints Wendy Yarno to Board of Directors
finance.yahoo.com - November 19 at 6:15 PM
Tarsus Pharmaceuticals, Inc. to Present at the Jefferies Virtual London Healthcare ConferenceTarsus Pharmaceuticals, Inc. to Present at the Jefferies Virtual London Healthcare Conference
feeds.benzinga.com - November 13 at 8:27 PM
Tarsus Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Full Exercise by the Underwriters of Option to Purchase Additional SharesTarsus Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Full Exercise by the Underwriters of Option to Purchase Additional Shares
finance.yahoo.com - October 23 at 9:35 AM
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.